RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Completed

Plain-English translation of NCT04620733 on ClinicalTrials.gov ↗ · Source last updated September 2024 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(134 sites)

United States

The Institute for Liver Health DBA Arizona Liver Health, Chandler, Arizona

Arkansas Diagnostic Center, Little Rock, Arkansas

Stanford University School of Medicine, Palo Alto, California

California Liver Research Institute, Pasadena, California

University of California, Davis Medical Center, Sacramento, California